BKYI vs RTX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BKYI exhibits weak financial health with a Piotroski F-Score of 4/9, indicating a fragile stability, and lacks an Altman Z-Score, raising unquantified distress risk. The company reports severe profitability issues, including a -67.34% profit margin, -137.69% ROE, and negative earnings across all recent quarters, despite a high gross margin of 78.40%. Revenue has declined 27.7% YoY, and earnings surprises have been consistently negative in the last four quarters, with an average miss of -17.33%. The stock trades at a price-to-book of 0.80, but this is misleading given the company’s deep losses and negative equity. Analysts have a target price of $2.00, but with only one analyst covering the stock and no consensus, this is not reliable.
RTX shows bearish fundamentals based on deterministic rules. Financial strength is stable (F-Score 5/9). Concerns include weak profitability or high valuation.
Compare Another Pair
Related Comparisons
BKYI vs RTX: Head-to-Head Comparison
This page compares BIO-key International, Inc. (BKYI) and RTX Corporation (RTX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.